EBITDA Margin % is calculated as EBITDA divided by its Revenue. Moolec Science's EBITDA for the
six
months ended in Dec. 2025 was $-7.7 Mil. Moolec Science's Revenue for the
six
months ended in Dec. 2025 was $5.2 Mil. Therefore, Moolec Science's EBITDA margin for the quarter that ended in Dec. 2025 was -147.93%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Moolec Science EBITDA Margin % Related Terms
Moolec Science EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Moolec Science's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLEC vs RVPH, CDIO, DRMA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Moolec Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Moolec Science's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (MLEC) has a EBITDA Margin % of -147.93% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #402 out of 945 companies in the Biotechnology industry, placing it in the top 42.5%.
Is Moolec Science's EBITDA Margin % too high?
Moolec Science's current EBITDA Margin % is -147.93%. Based on the distribution chart, Moolec Science ranks #402 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's EBITDA Margin % compare to RVPH and CDIO?
According to the Biotechnology industry distribution chart, Moolec Science ranks #402 out of 945 companies for EBITDA Margin %. This puts Moolec Science in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Moolec Science and its competitors. Moolec Science's current EBITDA Margin % is -147.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.62 — trading 91% below its estimated fair value. The current EBITDA Margin % is -147.93%. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Moolec Science (MLEC), the current EBITDA Margin % is -147.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.62 is trading 91% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
EBITDA Margin %: -147.93%
GF Value™: $84.84 vs. price of $7.62 (91% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
